

Craig T Morita

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1675488/publications.pdf>

Version: 2024-02-01

70
papers

8,945
citations

66315

42
h-index

102432

66
g-index

71
all docs

71
docs citations

71
times ranked

5890
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1 checkpoint blockade enhances adoptive immunotherapy by human V β 32V α 2 T cells against human prostate cancer. <i>OncImmunology</i> , 2021, 10, 1989789.	2.1	15
2	Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human V β 32V α 2 T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 1405.	2.2	16
3	Critical Roles for Coiled-Coil Dimers of Butyrophilin 3A1 in the Sensing of Prenyl Pyrophosphates by Human V β 32V α 2 T Cells. <i>Journal of Immunology</i> , 2019, 203, 607-626.	0.4	16
4	Determination of human $\hat{I}\hat{3}\hat{I}$ T cell-mediated cytotoxicity using a non-radioactive assay system. <i>Journal of Immunological Methods</i> , 2019, 466, 32-40.	0.6	4
5	Synthesis and Immunomodulatory Activity of Fluorine-containing Bisphosphonates. <i>ChemMedChem</i> , 2019, 14, 462-468.	1.6	7
6	Expansion of human $\hat{I}\hat{3}\hat{I}$ T cells for adoptive immunotherapy using a bisphosphonate prodrug. <i>Cancer Science</i> , 2018, 109, 587-599.	1.7	40
7	Abstract 3628: PD-1 checkpoint blockade therapy enhances adoptive immunotherapy by human V β 32V α 2 T cells against prostate tumors in a preclinical model. , 2018, , .		0
8	Enhancing adoptive cancer immunotherapy with V β 32V α 2 T cells through pulse zoledronate stimulation. , 2017, 5, 9.		49
9	Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug. <i>Scientific Reports</i> , 2017, 7, 5987.	1.6	49
10	Live Cell Labeling with Terpyridine Derivative Proligands to Measure Cytotoxicity Mediated by Immune Cells. <i>ChemMedChem</i> , 2017, 12, 2006-2013.	1.6	9
11	Necroptosis of Dendritic Cells Promotes Activation of $\hat{I}\hat{3}\hat{I}$ T Cells. <i>Journal of Innate Immunity</i> , 2016, 8, 479-492.	1.8	3
12	Targeting Cancer Cells with a Bisphosphonate Prodrug. <i>ChemMedChem</i> , 2016, 11, 2656-2663.	1.6	35
13	Anti-PD-1 and Anti-PD-L1 mAbs. , 2016, , 283-294.		1
14	Sensor Function for Butyrophilin 3A1 in Prenyl Pyrophosphate Stimulation of Human V β 32V α 2 T Cells. <i>Journal of Immunology</i> , 2015, 195, 4583-4594.	0.4	74
15	Metabolic Engineering of <i>Salmonella</i> Vaccine Bacteria To Boost Human V β 32V α 2 T Cell Immunity. <i>Journal of Immunology</i> , 2014, 193, 708-721.	0.4	22
16	Zoledronic acid-induced expansion of $\hat{I}\hat{3}\hat{I}$ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 677-687.	2.0	55
17	Chemo-Immunotherapeutic Antimalarials Targeting Isoprenoid Biosynthesis. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 423-427.	1.3	35
18	Butyrophilin 3A1 Plays an Essential Role in Prenyl Pyrophosphate Stimulation of Human V β 32V α 2 T Cells. <i>Journal of Immunology</i> , 2013, 191, 1029-1042.	0.4	142

#	ARTICLE	IF	CITATIONS
19	Comparison of $\hat{3}\hat{1}$ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid. <i>Cancer Science</i> , 2013, 104, 536-542.	1.7	50
20	Synthesis and immunological evaluation of the 4- $\hat{2}$ -glucoside of HMBPP. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 811-813.	1.0	1
21	Regulation and function of IL-17A- and IL-22-producing $\hat{3}\hat{1}$ T cells. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 2371-2390.	2.4	58
22	Indirect Stimulation of Human $\hat{3}\hat{2}\hat{1}$ T Cells through Alterations in Isoprenoid Metabolism. <i>Journal of Immunology</i> , 2011, 187, 5099-5113.	0.4	79
23	Lipophilic Pyridinium Bisphosphonates: Potent $\hat{3}\hat{1}$ T Cell Stimulators. <i>Angewandte Chemie - International Edition</i> , 2010, 49, 1136-1138.	7.2	63
24	$\hat{3}\hat{2}\hat{1}$ T Cell Receptor Recognition of Prenyl Pyrophosphates Is Dependent on All CDRs. <i>Journal of Immunology</i> , 2010, 184, 6209-6222.	0.4	107
25	Identification of an Important Immunological Difference between Virulent Varicella-Zoster Virus and Its Avirulent Vaccine: Viral Disruption of Dendritic Cell Instruction. <i>Journal of Immunology</i> , 2010, 185, 488-497.	0.4	18
26	Cytokine Requirements for the Differentiation and Expansion of IL-17A $\hat{3}\hat{1}$ and IL-22 $\hat{3}\hat{1}$ -Producing Human $\hat{3}\hat{2}\hat{1}$ T Cells. <i>Journal of Immunology</i> , 2010, 184, 7268-7280.	0.4	169
27	Phenotypic and functional alterations of $\hat{3}\hat{2}\hat{1}$ T cell subsets in patients with active nasopharyngeal carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1095-1107.	2.0	16
28	Phosphonosulfonates Are Potent, Selective Inhibitors of Dehydrosqualene Synthase and Staphyloxanthin Biosynthesis in <i>Staphylococcus aureus</i> . <i>Journal of Medicinal Chemistry</i> , 2009, 52, 976-988.	2.9	59
29	Photoaffinity Antigens for Human $\hat{3}\hat{1}$ T Cells. <i>Journal of Immunology</i> , 2008, 181, 7738-7750.	0.4	49
30	Preferential recognition of a microbial metabolite by human $\hat{3}\hat{2}\hat{1}$ T cells. <i>International Immunology</i> , 2007, 19, 657-673.	1.8	91
31	Nonpeptide antigens, presentation mechanisms, and immunological memory of human $\hat{3}\hat{2}\hat{1}$ T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. <i>Immunological Reviews</i> , 2007, 215, 59-76.	2.8	386
32	Synthesis of Pyrophosphate-Containing Compounds that Stimulate $\hat{3}\hat{2}\hat{1}$ T Cells: Application to Cancer Immunotherapy. <i>Medicinal Chemistry</i> , 2007, 3, 85-99.	0.7	28
33	Isoprenoid Biosynthesis as a Drug Target: $\hat{3}$ Bisphosphonate Inhibition of <i>Escherichia coli</i> K12 Growth and Synergistic Effects of Fosmidomycin. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 7331-7341.	2.9	52
34	Structural Studies of $\hat{3}\hat{2}\hat{1}$ T Cell Phosphoantigens. <i>Chemistry and Biology</i> , 2006, 13, 985-992.	6.2	23
35	Chemokine biology of NK cells and $\hat{3}\hat{1}$ T cells. , 2006, , 59-78.		2
36	Pyridinium-1-yl Bisphosphonates Are Potent Inhibitors of Farnesyl Diphosphate Synthase and Bone Resorption. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 2957-2963.	2.9	77

#	ARTICLE	IF	CITATIONS
37	Calmodulin kinase II regulates the maturation and antigen presentation of human dendritic cells. <i>Journal of Leukocyte Biology</i> , 2005, 78, 1397-1407.	1.5	43
38	A Crystallographic Investigation of Phosphoantigen Binding to Isopentenyl Pyrophosphate/Dimethylallyl Pyrophosphate Isomerase. <i>Journal of the American Chemical Society</i> , 2005, 127, 536-537.	6.6	12
39	fldA is an essential gene required in the 2-C-methyl-D-erythritol 4-phosphate pathway for isoprenoid biosynthesis. <i>FEBS Letters</i> , 2005, 579, 3802-3806.	1.3	79
40	Synthesis of chiral phosphoantigens and their activity in $\hat{I}\hat{3}\hat{I}$ T cell stimulation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 4471-4477.	1.0	20
41	Quantitative Structure-Activity Relationships for $\hat{I}\hat{3}\hat{I}$ T Cell Activation by Bisphosphonates. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 375-384.	2.9	114
42	Identification of guinea pig $\hat{I}\hat{3}\hat{I}$ T cells and characterization during pulmonary tuberculosis. <i>Veterinary Immunology and Immunopathology</i> , 2004, 102, 33-44.	0.5	7
43	Conservation of Nonpeptide Antigen Recognition by Rhesus Monkey $\hat{V}\hat{I}\hat{3}\hat{2}\hat{V}\hat{I}\hat{2}$ T Cells. <i>Journal of Immunology</i> , 2003, 170, 3696-3706.	0.4	52
44	Flexible migration program regulates $\hat{I}\hat{3}\hat{I}$ T-cell involvement in humoral immunity. <i>Blood</i> , 2003, 102, 3693-3701.	0.6	158
45	CD1-mediated $\hat{I}\hat{3}\hat{I}$ T Cell Maturation of Dendritic Cells. <i>Journal of Experimental Medicine</i> , 2002, 196, 1575-1584.	4.2	194
46	Adaptive Immune Response of $\hat{V}\hat{\gamma}$ $\hat{2}\hat{\Delta}$ T Cells During Mycobacterial Infections. <i>Science</i> , 2002, 295, 2255-2258.	6.0	355
47	Superantigen Recognition by $\hat{I}\hat{3}\hat{I}$ T Cells. <i>Immunity</i> , 2001, 14, 331-344.	6.6	50
48	MICA Engagement by Human $\hat{V}\hat{I}\hat{3}\hat{2}\hat{V}\hat{I}\hat{2}$ T Cells Enhances Their Antigen-Dependent Effector Function. <i>Immunity</i> , 2001, 15, 83-93.	6.6	398
49	Structural Features of Nonpeptide Prenyl Pyrophosphates That Determine Their Antigenicity for Human $\hat{I}\hat{3}\hat{I}$ T Cells. <i>Journal of Immunology</i> , 2001, 167, 36-41.	0.4	74
50	T cell receptor-dependent activation of human lymphocytes through cell surface ganglioside GT1b: implications for innate immunity. <i>European Journal of Immunology</i> , 2000, 30, 3199-3206.	1.6	6
51	Antigen recognition by human $\hat{I}\hat{3}\hat{I}$ T cells: pattern recognition by the adaptive immune system. <i>Seminars in Immunopathology</i> , 2000, 22, 191-217.	4.0	153
52	Self-Recognition of Cd1 by $\hat{I}\hat{3}\hat{I}$ T Cells. <i>Journal of Experimental Medicine</i> , 2000, 191, 937-948.	4.2	345
53	Recognition of nonpeptide prenyl pyrophosphate antigens by human $\hat{I}\hat{3}\hat{I}$ T cells. <i>Microbes and Infection</i> , 1999, 1, 175-186.	1.0	62
54	Human $\hat{I}\hat{3}\hat{I}$ T Cells Recognize Alkylamines Derived from Microbes, Edible Plants, and Tea. <i>Immunity</i> , 1999, 11, 57-65.	6.6	347

#	ARTICLE	IF	CITATIONS
55	The Syk family of protein tyrosine kinases in T-cell activation and development. Immunological Reviews, 1998, 165, 167-180.	2.8	242
56	Transendothelial chemotaxis of human $\alpha\beta$ and $\gamma\delta$ T lymphocytes to chemokines. European Journal of Immunology, 1998, 28, 104-113.	1.6	69
57	Direct presentation of non-peptide prenyl pyrophosphate antigens to human $\gamma\delta$ T cells. Research in Immunology, 1996, 147, 347-353.	0.9	48
58	Recognition of nonpeptide antigens by T cells. Journal of Molecular Medicine, 1996, 74, 223-231.	1.7	31
59	T-cell recognition of non-peptide antigens. Current Opinion in Immunology, 1996, 8, 510-516.	2.4	89
60	Interactions of human alpha/beta and gamma/delta T lymphocyte subsets in shear flow with E-selectin and P-selectin.. Journal of Experimental Medicine, 1996, 183, 1193-1203.	4.2	66
61	Natural and synthetic non-peptide antigens recognized by human $\gamma\delta$ T cells. Nature, 1995, 375, 155-158.	13.7	959
62	Direct presentation of nonpeptide prenyl pyrophosphate antigens to human $\gamma\delta$ T cells. Immunity, 1995, 3, 495-507.	6.6	453
63	Recognition of a lipid antigen by CD1-restricted $\alpha\beta$ T cells. Nature, 1994, 372, 691-694.	13.7	962
64	Nonpeptide ligands for human gamma delta T cells.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 8175-8179.	3.3	369
65	CD1b restricts the response of human CD4 ⁺ $\gamma\delta$ T lymphocytes to a microbial antigen. Nature, 1992, 360, 593-597.	13.7	574
66	Functionally distinct subsets of human $\gamma\delta$ T cells. European Journal of Immunology, 1991, 21, 2999-3007.	1.6	106
67	Evidence for clonal selection of gamma/delta T cells in response to a human pathogen.. Journal of Experimental Medicine, 1991, 174, 683-692.	4.2	92
68	Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire.. Journal of Experimental Medicine, 1990, 171, 1597-1612.	4.2	500
69	Recognition of mycobacterial antigens by $\gamma\delta$ T cells. Research in Immunology, 1990, 141, 645-651.	0.9	11
70	ANTIRETINOBLASTOMA MONOCLONAL ANTIBODIES. Retina, 1983, 3, 200-205.	1.0	5